Pilot study of interferon gamma for chronic hepatitis C

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C remains a significant global health challenge.
• Limited treatment options exist for patients unresponsive to interferon alfa-based therapies.
• Interferon alfa and ribavirin are standard treatments, but relapse and non-response rates necessitate alternative strategies.

Purpose of the Study:

• To evaluate the antiviral activity of interferon gamma in chronic hepatitis C patients.
• To assess the safety and tolerability of interferon gamma in this patient population.
• To determine if interferon gamma can impact Hepatitis C Virus (HCV) RNA levels.

Main Methods:

• Pilot study involving 14 patients with chronic hepatitis C (genotype 1).
• Patients had previously failed interferon alfa and ribavirin therapy.
• Interferon gamma 1b was administered subcutaneously at 100, 200, or 400 microg thrice weekly for 4 weeks.
• HCV RNA levels, aminotransferase levels, neutrophil counts, and hematocrit were monitored.

Main Results:

• No significant change in geometric mean HCV RNA levels was observed.
• Serum aminotransferase levels remained unchanged.
• Significant decreases in neutrophil counts (-41%) and hematocrit (-5%) were noted.
• Common side effects included low-grade fever and malaise, with no serious adverse events.

Conclusions:

• Interferon gamma, at doses of 100-400 microg thrice weekly, demonstrated no antiviral efficacy in chronic hepatitis C patients.
• The treatment was relatively well-tolerated but did not alter HCV RNA levels in non-responders to interferon alfa-based therapies.
• Further research into alternative therapies for treatment-resistant chronic hepatitis C is warranted.